Table 1:
Patient characteristics and clinical baseline data
| Study population, n = 58 | |
|---|---|
| Gender, n (%) | |
| Female | 22 (37.9) |
| Male | 36 (61.1) |
| Age (years) | 49.5 (13.0) |
| BSA (m2), mean (SD) | 1.9 (0.2) |
| BMI (kg/m²), mean (SD) | 25.4 (4.3) |
| Karnofsky index, n (%) | |
| 70% | 3 (5.2) |
| 80% | 11 (19.0) |
| 90% | 29 (50.0) |
| 100% | 12 (20.7) |
| Missing | 3 (5.2) |
| ECOG status, n (%) | |
| 0 | 41 (70.7) |
| 1 | 14 (24.1) |
| Missing | 3 (5.2) |
| Pleural tumour manifestation, n (%) | |
| Primary tumour | 50 (86.2) |
| Recurrence | 8 (13.8) |
| Side of tumour, n (%) | |
| Left | 29 (50.0) |
| Right | 29 (50.0) |
| Histology,an (%) | |
| Thymoma | 42 (72.4) |
| Thymic carcinoma | 15 (25.9) |
| Atypical carcinoid of the thymus | 1 (1.7) |
| CRS | |
| Surgical procedure, n (%) | |
| P/D | 12 (20.7) |
| eP/D | 44 (75.9) |
| EPP | 2 (3.4) |
| Resection of, n (%) (>100%) | |
| Diaphragm | 37 (63.8) |
| Pericardium | 27 (46.6) |
| Chest wall | 3 (5.2) |
| Lung (wedge/atypical) | 24 (41.4) |
| Alloplastic reconstruction/replacement of, n (%) | |
| Diaphragm | 19 (32.8) |
| Pericardium | 22 (37.9) |
| Resection status, n (%) | |
| R0/1 | 49 (84.5) |
| R2 | 9 (15.5) |
| Blood loss,b median (IQR) | 575 (100–950) |
| Transfusion PC#,b median (IQR) | 0 (0–0) |
| Transfusion FPP#,b median (IQR) | 2 (0–4) |
| Transfusion PRBC#,b median (IQR) | 1 (0–2) |
| Intraoperative complication, n (%) | |
| No | 57 (98.3) |
| Yes | 1 (1.7) |
| HITOC | |
| Duration of HITOC, median (IQR) (min) | 60 (60–60) |
| Temperature perfusate (°C) | |
| Minimum, median (IQR) (n = 56) | 42.0 (41.5–42.0) |
| Maximum (median, IQR) (n = 56) | 42.0 (42.0–42.5) |
| Pump flow (ml/min) | |
| Minimum, median (IQR) (n = 56) | 1200 (1000–1375) |
| Maximum, median (IQR) (n = 56) | 1200 (1000–1500) |
| Perfusion volume (ml), median (IQR) (n = 58) | 5000 (4000–5000) |
| Chemotherapeutic agents, n (%) | |
| Cisplatin | 38 (65.5) |
| Cisplatin + doxorubicin | 20 (34.5) |
| Total dosages of chemotherapeutic agents (mg/m2 BSA), median (IQR) | |
| Cisplatin (n = 58) | 120 (100.0–175.0) |
| Doxorubicin (n = 20) | 35.3 (32.3–38.1) |
| Cisplatin dosage (mg/m2 BSA), n (%) | |
| Low dose ≤125 | 30 (51.7) |
| High dose >125 | 28 (48.3) |
| Complications during HITOC, n (%) | |
| No | 58 (100) |
| Yes | 0 (0) |
a
WHO histological classification [14].
b
Blood loss and transfusion was recorded in n = 24 patients (41.4%).
BMI: body mass index; BSA: body surface area; CRS: cytoreductive surgery; ECOG: Eastern Cooperative Oncology Group; eP/D: extended pleurectomy/decortication; EPP: extrapleural pneumonectomy; HITOC: hyperthermic intrathoracic chemotherapy; IQR: interquartile range; P/D: pleurectomy/decortication; SD: standard deviation; PC: platelet concentrate; PRBC: packed red blood cells; FFP: fresh frozen plasma; OR: operation room.